SIRIAM Formulation Design Philosophy

The formulation of a SIRIAM topical product is not driven by the selection of active ingredients. Instead, each formulation is developed through a structured design process in which anatomy, neurodermal architecture and pharmaceutical engineering are integrated into a reproducible formulation strategy.

The objective is to create formulations that are consistent across the platform while allowing regional specialization where clinically and anatomically justified.

This philosophy ensures that future formulations remain coherent with the overall SIRIAM Platform Standards, regardless of future modifications in ingredient selection or pharmaceutical technology.

Every SIRIAM formulation follows the same design hierarchy.

Clinical Purpose

↓

Clinical Assessment

↓

Segment Prioritization

↓

Metameric Foundation

↓

Application Field

↓

Neurodermal Application Zones

↓

Application Sequence

↓

DUO Strategy

↓

Functional Matrix

↓

Vehicle Architecture

↓

Structural Matrix

↓

Regional Signature Matrix

↓

Final Pharmaceutical Formulation

Each level builds upon the previous one.

Changes at a lower level shall never compromise the integrity of the higher design principles.

Every formulation is developed according to five fundamental principles.

Principle 1 — Anatomy First

Anatomical design always precedes pharmaceutical formulation.

No ingredient is selected before the anatomical target has been defined.

Principle 2 — Function Before Composition

The intended biological function determines the formulation architecture.

Ingredient selection serves the function and is never the starting point of development.

Principle 3 — Platform Consistency

All formulations share a common structural platform.

Regional diversity is introduced only where functionally required.

This minimizes unnecessary variability while preserving anatomical specificity.

Principle 4 — Pharmaceutical Robustness

Every formulation should be technically reproducible.

The formulation must be capable of standardized preparation, packaging and dispensing.

Pharmaceutical quality is considered an integral part of formulation design.

Principle 5 — Continuous Evolution

SIRIAM formulations are considered evolving pharmaceutical designs.

Future modifications are expected as new pharmaceutical, anatomical and clinical knowledge becomes available.

Each formulation consists of four complementary layers.

Layer I

Clinical Architecture

Defines:

Clinical Purpose

Segment Prioritization

Application Field

Layer II

Functional Architecture

Defines:

Release

Integration

Maintenance

Layer III

Structural Architecture

Defines:

Vehicle

Structural Matrix

Pharmaceutical properties

Layer IV

Regional Architecture

Defines the anatomical identity of the formulation through its Regional Signature Matrix.

The pharmaceutical formulation represents the final translation of the preceding design architecture.

Its objective is not only to incorporate active substances but also to ensure:

patient-friendly application.

Pharmaceutical engineering therefore constitutes the final stage of formulation design rather than its starting point.

• stability;
• homogeneity;
• reproducibility;
• compatibility of ingredients;
• appropriate viscosity;
• standardized dispensing;

The SIRIAM Platform is developed through iterative design cycles.

Each development cycle may incorporate observations arising from:

exploratory physiological measurements, such as surface EMG, when incorporated into the research program.

Modifications are introduced only after multidisciplinary review and are documented through the platform's version-control system.

• anatomical refinement;
• pharmaceutical optimization;
• preparation experience;
• packaging performance;
• clinical observations;
• patient-reported outcomes;

Each formulation progresses through successive stages of maturity.

Concept Design

Prototype Formulation

Professional Review

Pharmaceutical Optimization

Pilot Batch

Clinical Evaluation

Technical Revision

Validated Master Formula

Only the final stage is released as a controlled pharmaceutical formulation.

Within the SIRIAM Platform, the magistral formulation is regarded as the practical implementation of the design architecture.

The magistral formulation itself is not the origin of the concept but its pharmaceutical realization.

Consequently, modifications to ingredient concentrations may occur during development without altering the underlying clinical, anatomical or neurodermal design philosophy.